Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Daily Feeds
Calendars
Economic Indicators
Class Actions
Calculators
Education
About Us
Working with TipRanks
Follow Us
Ardelyx (ARDX)
NASDAQ:ARDX
ARDX Stock Chart & Stats
Day’s Range― - ―
52-Week Range$4.32 - $10.13
Previous CloseN/A
Volume1.36M
Average Volume (3M)4.96M
Market Cap
$1.31B
Enterprise Value$1.54B
Total Cash (Recent Filing)N/A
Total Debt (Recent Filing)N/A
Price to Earnings (P/E)―
Beta1.49
Next Earnings
Mar 05, 2025EPS Estimate
<0.01Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.31
Shares Outstanding236,854,260
10 Day Avg. Volume5,952,554
30 Day Avg. Volume4,964,262
Standard Deviation0.22
R-Squared0.04
Alpha0.01
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)5.19
Price to Cash Flow (P/CF)652.40
P/FCF Ratio898.00
Enterprise Value/Market Cap1.18
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit14.43
Enterprise Value/Ebitda-29.01
Forecast
1Y Price Target
$8.38Price Target Upside58.41% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering5
---
Bulls Say, Bears Say
Bulls Say
Growth PotentialOver one third of IBS-C patients are potential candidates for Ibsrela, which underscores its potential to exceed management’s longer-term guidance of ~$1B peak US sales for Ibsrela.
Market PerformanceXPHOZAH's net sales revenue in the U.S. was significantly higher than estimated, indicating strong market performance.
Revenue GrowthManagement reiterated peak US revenue guidance of over $1 billion for Ibsrela and specified peak US revenue guidance of approximately $750 million for Xphozah.
Bears Say
Investor SentimentA significant overhang on investor sentiment and the stock is expected until there is a resolution to the uncertainty around Medicare patient access for XPHOZAH.
Reimbursement UncertaintyUncertainty surrounds XPHOZAH's reimbursement status for Medicare patients, which affects a large portion of its addressable market.
Stock Rating DowngradeAnalysts anticipate a substantial drop in XPHOZAH sales due to its inclusion in the Medicare bundle, leading to a downgrade of the stock rating.
---
Ownership Overview
2.57% Insiders
19.26% Mutual Funds
0.35% Other Institutional Investors
64.39% Public Companies and Individual Investors
Risk Analysis
Main Risk Category
Legal & RegulatoryLitigation, compliance, new legislation, and taxation risks
Website Traffic
Sorry, No Data AvailableThere is no website visitor data available for this stock.
---
ARDX FAQ
What was Ardelyx’s price range in the past 12 months?
Ardelyx lowest stock price was $4.32 and its highest was $10.13 in the past 12 months.
What is Ardelyx’s market cap?
Ardelyx’s market cap is $1.31B.
When is Ardelyx’s upcoming earnings report date?
Ardelyx’s upcoming earnings report date is Mar 05, 2025 which is in 29 days.
How were Ardelyx’s earnings last quarter?
Ardelyx released its earnings results on Oct 31, 2024. The company reported $0 earnings per share for the quarter, beating the consensus estimate of -$0.049 by $0.049.
Is Ardelyx overvalued?
According to Wall Street analysts Ardelyx’s price is currently Undervalued.
Does Ardelyx pay dividends?
Ardelyx does not currently pay dividends.
What is Ardelyx’s EPS estimate?
Ardelyx’s EPS estimate is <0.01.
How many shares outstanding does Ardelyx have?
Ardelyx has 236,854,260 shares outstanding.
What happened to Ardelyx’s price movement after its last earnings report?
Ardelyx reported an EPS of $0 in its last earnings report, beating expectations of -$0.049. Following the earnings report the stock price went up 3.748%.
Which hedge fund is a major shareholder of Ardelyx?
Among the largest hedge funds holding Ardelyx’s share is Oracle Investment Management Inc. It holds Ardelyx’s shares valued at 9M.
---
Ardelyx Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$8.38 (58.41% Upside)
$8.38 (58.41% Upside)
Blogger Sentiment
Bullish
ARDX Sentiment 93%
Sector Average 71%
Sector Average 71%
Hedge Fund Trend
Increased
By 86.2K Shares
Last Quarter.
Last Quarter.
Insider Transactions
Bought Shares
Worth $2.2M over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Neutral
Last 7 Days ▼ 1.2%
Last 30 Days ▲ 1.4%
Last 30 Days ▲ 1.4%
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-34.98%
12-Months-Change
Fundamentals
Return on Equity
-45.85%
Trailing 12-Months
Asset Growth
27.12%
Trailing 12-Months
Company Description
Ardelyx
Ardelyx, Inc. is a biopharmaceutical company, which engages in the research, development and commercialization of medicine for the treatment of renal diseases. It focuses on the formulation of programs directed toward treating gastrointestinal and irritable bowel syndrome with constipations. Its product portfolio includes tenapanor, which is an experimental medication that works exclusively in the gut and is in late-stage clinical development. The company was founded by Dominique Charmot, Peter G. Schultz, and Jean M. Frechet on October 17, 2007 and is headquartered in Fremont, CA.
---
ARDX Earnings Call
Q3 2024
0:00 / 0:00
Earnings Call Sentiment|Positive
The earnings call highlighted significant revenue growth and strong market reception for Ardelyx's products, IBSRELA and XPHOZAH. However, challenges remain with CMS coverage uncertainties and increased operating expenses. Legal and legislative efforts to address policy changes are ongoing.Read More>---
ARDX Stock 12 Month Forecast
Average Price Target
$8.38
▲(58.41% Upside)
Technical Analysis
Best Analysts Covering ARDX
1 Year
1 Year Success Rate
8/16 ratings generated profit
1 Year Average Return
+59.75%
reiterated a buy rating 3 months ago
Copying Yigal Nochomovitz's trades and holding each position for 1 Year would result in 50.00% of your transactions generating a profit, with an average return of +59.75% per trade.
---